Clinical Trial

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of APG-5918 in Healthy Subjects or Anemic Patients.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-03-06; most recent amendment 2026-04-12.
Status change: Not Yet Recruiting → Recruiting 2023-03-23
Trial Details
NCT Number NCT05773586
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Anemia
Enrollment 105 participants
Start Date 2023-03-13
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-15